Status:
COMPLETED
Study Evaluating the Safety of Lecozotan SR in Healthy Young and Elderly Subjects
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Alzheimer Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
To assess the safety, tolerability and pharmacokinetics of single and multiple ascending oral doses of lecozotan SR in healthy young and elderly subjects.
Eligibility Criteria
Inclusion
- Young subjects: Men aged 18 to 45 years. -Elderly subjects: Men and women ≥ 65 years of age. -Body mass index in the range of 18 to 30 kg/m2 and body weight ≥ 50 kg. -Healthy as determined by the investigator.
Exclusion
- History of any neuropsychiatric disorder. -History of drug or alcohol abuse.
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00366483
Start Date
May 1 2006
Last Update
March 16 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Paris, France